Alpha-1-antitrypsin deficiency: increasing awareness and improving diagnosis

by Timm Greulich, Claus F. Vogelmeier
Published 2016-02-01

Exacerbations of COPD

by Christian Viniol, Claus F. Vogelmeier
Published 2018-03-01

Comorbid Influences on Generic Health-Related Quality of Life in COPD: A Systematic Review.

by Manuel B Huber, Margarethe E Wacker, Claus F Vogelmeier, Reiner Leidl
Published 2015-01-01

Excess costs of comorbidities in chronic obstructive pulmonary disease: a systematic review.

by Manuel B Huber, Margarethe E Wacker, Claus F Vogelmeier, Reiner Leidl
Published 2015-01-01

Real world evaluation of a novel lateral flow assay (AlphaKit® QuickScreen) for the detection of alpha-1-antitrypsin deficiency

by Timm Greulich, Francisco Rodríguez-Frias, Irene Belmonte, Andreas Klemmer, Claus F. Vogelmeier, Marc Miravitlles
Published 2018-08-01

Efficacy of indacaterol/glycopyrronium versus salmeterol/fluticasone in current and ex-smokers: a pooled analysis of IGNITE trials

by David M.G. Halpin, Claus F. Vogelmeier, Karen Mezzi, Pritam Gupta, Konstantinos Kostikas, Jadwiga A. Wedzicha
Published 2021-02-01

High eosinophil blood counts are associated with a shorter length of hospital stay in exacerbated COPD patients – a retrospective analysis

by Timm Greulich, Julia Tüffers, Sina Mager, Anna Eder, Michael Maxheim, Peter Alter, Bernd Schmeck, Claus F. Vogelmeier
Published 2020-05-01

Prevalence of overuse of short-acting beta-2 agonists (SABA) and associated factors among patients with asthma in Germany

by Heinrich Worth, Carl-Peter Criée, Claus F. Vogelmeier, Peter Kardos, Eva-Maria Becker, Karel Kostev, Ingo Mokros, Andrea Schneider
Published 2021-04-01

Benefits of pulmonary rehabilitation in COVID-19: a prospective observational cohort study

by Rainer Gloeckl, Daniela Leitl, Inga Jarosch, Tessa Schneeberger, Christoph Nell, Nikola Stenzel, Claus F. Vogelmeier, Klaus Kenn, Andreas R. Koczulla
Published 2021-05-01

Evaluation of exacerbations and blood eosinophils in UK and US COPD populations

by Claus F. Vogelmeier, Konstantinos Kostikas, Juanzhi Fang, Hengfeng Tian, Bethan Jones, Christopher Ll Morgan, Robert Fogel, Florian S. Gutzwiller, Hui Cao
Published 2019-08-01

Comparative effectiveness of triple therapy versus dual bronchodilation in COPD

by Jaco Voorham, Massimo Corradi, Alberto Papi, Claus F. Vogelmeier, Dave Singh, Leonardo M. Fabbri, Marjan Kerkhof, Janwillem H. Kocks, Victoria Carter, David Price
Published 2019-08-01

Uric acid, lung function, physical capacity and exacerbation frequency in patients with COPD: a multi-dimensional approach

by Kathrin Kahnert, Peter Alter, Tobias Welte, Rudolf M. Huber, Jürgen Behr, Frank Biertz, Henrik Watz, Robert Bals, Claus F. Vogelmeier, Rudolf A. Jörres
Published 2018-06-01

Health-related quality of life associates with change in FEV1 in COPD: results from the COSYCONET cohort

by Johanna I. Lutter, Rudolf A. Jörres, Kathrin Kahnert, Larissa Schwarzkopf, Michael Studnicka, Stefan Karrasch, Holger Schulz, Claus F. Vogelmeier, Rolf Holle, for the COSYCONET Study Group
Published 2020-05-01

Treatment response in COPD: does FEV1 say it all? A post hoc analysis of the CRYSTAL study

by Konstantinos Kostikas, Timm Greulich, Alexander J. Mackay, Nadine S. Lossi, Maryam Aalamian-Mattheis, Xavier Nunez, Veronica A. Pagano, Francesco Patalano, Andreas Clemens, Claus F. Vogelmeier
Published 2019-02-01

Pulmonary rehabilitation in long COVID: more than just natural recovery!?

by Rainer Gloeckl, Daniela Leitl, Inga Jarosch, Tessa Schneeberger, Christoph Nell, Nikola Stenzel, Ayham Daher, Michael Dreher, Claus F. Vogelmeier, Klaus Kenn, Andreas R. Koczulla
Published 2021-08-01

Effects of airway obstruction and hyperinflation on electrocardiographic axes in COPD

by Peter Alter, Henrik Watz, Kathrin Kahnert, Klaus F. Rabe, Frank Biertz, Ronald Fischer, Philip Jung, Jana Graf, Robert Bals, Claus F. Vogelmeier, Rudolf A. Jörres
Published 2019-03-01

Chronic obstructive pulmonary disease guidelines in Europe: a look into the future

by Marc Miravitlles, Nicolas Roche, João Cardoso, David Halpin, Zaurbek Aisanov, Hannu Kankaanranta, Vladimir Kobližek, Paweł Śliwiński, Leif Bjermer, Michael Tamm, Francesco Blasi, Claus F. Vogelmeier
Published 2018-01-01

Early and sustained symptom improvement with umeclidinium/vilanterol monotherapy in COPD: a analysis of the EMAX randomised controlled trial

by Edward M Kerwin, Isabelle H Boucot, Claus F Vogelmeier, Francois Maltais, Ian P Naya, Lee Tombs, Paul W Jones, David A Lipson, Tom Keeley, Leif Bjermer
Published 2020-05-01

Design and application of an MR reference phantom for multicentre lung imaging trials.

by Simon M F Triphan, Jürgen Biederer, Kerstin Burmester, Iven Fellhauer, Claus F Vogelmeier, Rudolf A Jörres, Hans-Ulrich Kauczor, Claus P Heußel, Mark O Wielpütz, Bertram J Jobst
Published 2018-01-01

Impact of baseline COPD symptom severity on the benefit from dual mono-bronchodilators: an analysis of the EMAX randomised controlled trial

by Claus F. Vogelmeier, Edward M. Kerwin, Leif H. Bjermer, Lee Tombs, Paul W. Jones, Isabelle H. Boucot, Ian P. Naya, David A. Lipson, Chris Compton, Neil Barnes, François Maltais
Published 2020-11-01